The role of combination antihypertensive therapy and the progression of renal disease hypertension looking toward the next millennium

American Journal of Hypertension

Volumn 11, Issue 10 II SUPPL., 1998, Pages

  Bakris, George L ^a,b  

^a RUSH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Blood pressure control; Combination therapy; Compliance; Renal disease

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; NIFEDIPINE; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR HYPERTENSION; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOLOGY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES;

EID: 0031772831     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(98)00190-3     Document Type: Article

References (23)

1. Harris M: Diabetes in America, 2nd ed. National Institutes of Health, Washington DC, 1995, NIH publication 95-1468, pp 1-19.
2. Nelson RG, Knowler WC, Pettit DJ, Bennett PH: Kidney diseases in diabetes, in Harris M (ed): Diabetes in America, 2nd ed. National Institutes of Health, Washington DC, 1995, pp 349-400.
3. National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease: 1995 update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 1996;156:1938-1947.
4. Joint National Committee: Joint National Committee Report on the Diagnosis, Prevention, and Treatment of Hypertension (JNC VI). Arch Intern Med 1997;157:2413-2446.
5. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the MDRD Group: Achievement and safety of a low blood pressure goal in chronic renal disease: the modification of diet in renal disease study group. Hypertension 1997;29:641-650.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
7. Hebert LA, Bain RP, Verme D, et al for the Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994;46:1688-1693.
8. Epstein M, Bakris GL: Newer approaches to antihypertensive therapy using fixed-dose combination therapy: future perspectives. Arch Intern Med 1996;156:1969-1978.
9. Burt VL, Cutler JA, Higgins M, et al: Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Hypertension 1995; 26:60-69.
10. Bakris GL, Mehler P, Schrier R: Hypertension and diabetes, in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney, 6th ed. Little Brown and Company, Boston, 1996, pp 1281-1328.
11. Jyothirmayi GN, Reddi AS: Effect of diltiazem on glomerular heparin sulfate and albuminuria in diabetic rats. Hypertension 1993;21:765-802.
12. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium channel blockers. Nephrol Dial Transpl (in press).
13. Makrilakis C, Bakris GL: Calcium channel blockers: are they created equal with regard to slowing progression of diabetic nephropathy, in Epstein M (ed): Calcium Antagonists in Clinical Medicine, Hanley and Belfus Publishers, Philadelphia, 1998, pp 273-290.
14. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995;96:793-800.
15. Bakris GL, Griffin K, Picken M, Bidani A: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997;15:1181-1185.
16. Picken M, Griffin K, Bakris GL, Bidani A: Comparative effects of four different calcium antagonists on progression of renal disease in a remnant kidney model (abst). J Am Soc Nephrol 1996;7:1586.
17. Anderson S. Rennke HG, Brenner BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992;41:891-897.
18. Dworkin LD, Tolbert E, Recht PA, et al: Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 1996;27:245-250.
19. Jerums G on behalf of the Melbourne Diabetic Ne-phropathy Study Group: ACE inhibitors versus calcium channel blockade (abst). Nephrology 1997;3:S124.
20. Packer M, O Connor CM, Ghali JK, et al for The Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
21. Carmines PK, Navar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989;256:F1015-F1020.
22. Munter K, Hergenroder S, Jochims K, Kirchengast M: Individual and combined effects of verapamil or trandolapril on glomerular morphology and function in the stroke prone rat. J Am Soc Nephrol 1996;7:681-686.
23. Bakris GL, Weir MR, DeQuattro V, et al: Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolapril or calcium antagonist, verapamil alone or in a fixed dose combination in patients with diabetic nephropathy: a randomized multicentered study (abst). J Am Soc Nephrol 1996;7:1546.